The manufacturer of Mounjaro takes a break of weight loss drugs in the United Kingdom | Pharmaceutical industry
The manufacturer of the weight loss medication Mounjaro paused in the United Kingdom before a significant increase in prices for processing next month.
The American pharmaceutical company Eli Lilly is expected to increase the price of the British drug list up to 170% compared to September, in the middle of a White House push to bring drug manufacturers to increase the prices of medicines in Europe to allow price reductions in the United States.
The company said that to manage its supply and ensure that patients have maintained access, it had in place allowances for pharmacies and providers who ordered the company’s medicines.
There have been legal protections to prevent inappropriate storage of drugs by providers, said Eli Lilly. He plans to resume orders on September 1.
The price increase could lead to a month from the highest dose of the drug from £ 122 to £ 330 ($ 165 to $ 445).
Eli Lilly would have told his two British wholesalers to temporarily stop taking orders after the request has skyrocketed before the entry into force of the price increase on September 1. The pharmacies said that there had been the purchase of panic of the medication since the prices announcement this month.
People using Mounjaro have been warned of spending sellers on the hidden economy or bulk purchases.
While many pay for medication in the United Kingdom, it has become available on the NHS at the end of June, and Eli Lilly says that the higher price will not affect those who will get it in the health service.
Mounjaro – also known by his generic name shooting – has become a popular alternative to the best known weight loss medication, Ozempic. The two drugs, which are taken as weekly injections, were developed in the form of treatments for type 2 diabetes.
When launched in Great Britain in February 2024, Eli Lilly accepted a “considerably lower” list price for his other European markets to stop delays in the availability of the drug by the NHS.
The increase in the list of the list will align it more coherently, said the company, although it added that the NHS would not pay the new higher price to guarantee continuous access to persons with obesity and type 2 diabetes which received it through the health service.
On July 31, Donald Trump sent letters to 17 of the world’s largest drug manufacturers, including Eli Lilly and Novo Nordisk, demanding Americans’ prices reductions in the 60 days.
In May, the American president told journalists that a friend in London told him that he had bought the “fatty medication” for $ 88, against $ 1,300 in New York.
